医学
胶质母细胞瘤
单中心
血脑屏障
麻醉
外科
重症监护医学
内科学
中枢神经系统
癌症研究
作者
Christian Ferreira,Marcio Yuri Ferreira,Faith Singh,Tamika Wong,S. Bokil,Sara Massimo,Julianna Cavallaro,Olivia Albers,Randy S. D’Amico,David J. Langer,John A. Boockvar,Yafell Serulle
标识
DOI:10.1136/jnis-2025-023068
摘要
Background Newly diagnosed glioblastoma (ndGBM) remains one of the most challenging malignancies to treat. Since the majority of patients experience tumor recurrence (rGBM) after first-line therapy, advancements in both initial and salvage treatments are essential. Objective We report our single-center experience on the feasibility and safety of superselective intra-arterial cerebral infusion (SIACI) with bevacizumab or cetuximab after osmotic blood–brain barrier disruption (oBBBd). Methods Partial results of three distinct trials (anonymized for blinded review) were analyzed. All patients were histopathologically confirmed to have either ndGBM or previously diagnosed ndGBM that progressed to rGBM despite standard therapy and had aKarnofsky Performance Status (KPS)≥70. All patients were admitted on the same day of the surgery, and the intervention followed similar steps in all included patients. Under general anesthesia, after oBBBd with mannitol, patients received SIACI. Results Between October 2014 and March 2024, 70 patients with a mean age of 56.2±12.4 years (range: 19–78) underwent successful treatment, encompassing 139 SIACIs and 246 infusions. All planned SIACIs were completed successfully. Forty-one patients with rGBM received bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SIACI. In 133 of 139 SIACIs (95.7%), patients were discharged home with a length of stay of 1 day. The incidence of patients who experienced procedure-related and drug-related adverse events was 11.4% and 8.6%, respectively. No procedure-related deaths occurred. Conclusion In our single-center experience, comprising the largest cohort of bevacizumab or cetuximab SIACI treatment for rGBM and ndGBM, this promising and cutting-edge intervention is highly feasible and safe.
科研通智能强力驱动
Strongly Powered by AbleSci AI